Clinical trials: DME
Diabetic Macular Edema
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
To assess the safety of repeated iCo-007 intravitreal injections in treatment of subjects with diabetic macular edema as monotherapy and in combination with ranibizumab or laser photocoagulation To assess the change in visual…
- Trial name
- iDEAL (NCT01565148)
- Testing
- iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- INTEGRAL (NCT05063734)
- Testing
- THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level
- Where
- 25 sites in United States, Estonia and 3 more
- Volunteers
- 16 people
- Sponsor
- Oxurion
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Diabetic Macular Edema
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME).
- Trial name
- DA VINCI (NCT00789477)
- Testing
- Laser Photocoagulation, Intravitreal Aflibercept Injection
- Where
- 47 sites in United States, Austria and 1 more
- Volunteers
- 221 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME).
- Trial name
- NCT00407381
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 20 sites in United States
- Volunteers
- 126 people
- Sponsor
- Johns Hopkins University
Diabetic Macular Edema
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema
This study is an interventional, prospective randomized study comparing the dexamethasone implant to intravitreal aflibercept. Subjects will have an initial single injection of aflibercept and will be randomized if diabetic…
- Trial name
- PRECISION (NCT04411693)
- Testing
- Dexamethasone implant, Aflibercept
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Retinal Vein Occlusion, Diabetic Macular Edema
Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
This interventional study will evaluate the retinal vascular dynamics associated with Intravitreal Aflibercept Injection (IAI) therapy in eyes with diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion…
- Conditions
- Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
- Trial name
- PERMEATE (NCT02503540)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Justis Ehlers
Diabetic Macular Edema
Phase II Combination Steroid and Anti-VEGF for Persistent DME
Although anti-vascular endothelial growth factor (VEGF) therapy is generally effective as treatment for center-involved diabetic macular edema (DME), a substantial proportion of anti-VEGF-treated eyes with DME do not achieve…
- Trial name
- NCT01945866
- Testing
- intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant
- Where
- 56 sites in United States
- Volunteers
- 129 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular…
- Trial name
- REVEAL (NCT00989989)
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 35 sites in China, Hong Kong and 4 more
- Volunteers
- 396 people
- Sponsor
- Novartis
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
- Trial name
- RESOLVE (NCT00284050)
- Testing
- Ranibizumab 0.3 mg, Ranibizumab 0.5 mg
- Where
- Switzerland
- Volunteers
- 151 people
- Sponsor
- Novartis
Diabetic Macular Edema
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
To explore a more clinical feasible treatment regime with ranibizumab for DME to provide satisfactory treatment effect with a lower number of visits and injections.
- Trial name
- SALUTE-D (NCT02262260)
- Testing
- Labeled regime arm, Wait and Extend regime arm
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009; NCT01363440) end-point.
- Trial name
- NCT02299336
- Testing
- Aflibercept, Focal Laser
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Greater Houston Retina Research
Diabetic Macular Edema
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan…
- Trial name
- DAVE (NCT01552408)
- Testing
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- David M. Brown, M.D.
Diabetic Macular Edema
A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
Researchers are looking for a better way to treat people who have diabetic macular edema (DME). Diabetic macular edema (DME) is a complication of diabetes.
- Trial name
- VISION-AF (NCT05511038)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 10 sites in India
- Volunteers
- 100 people
- Sponsor
- Bayer
Diabetic Macular Edema
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks…
- Trial name
- ROTATED (NCT03340610)
- Testing
- Alflibercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Wet Macular Degeneration, Age-related Macular Degeneration
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related…
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02571972
- Testing
- Dorzolamide-timolol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wills Eye
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema (DME)
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
- Trial name
- NCT04739306
- Testing
- CT-P42, Eylea
- Where
- Slovakia
- Volunteers
- 348 people
- Sponsor
- Celltrion